natgillin/translations-raw huggingface dataset:
If you take too many tablets talk to a doctor or go to hospital straight away. 
Če ste vzeli večji odmerek, se posvetujte z zdravnikom ali pojdite takoj v bolnišnico.
If you forget to take Iasibon 
Če ste pozabili vzeti zdravilo Iasibon
In the prevention of skeletal events in patients with breast cancer and bone metastases, treatment is most frequently associated with asthenia followed by rise in body temperature and headache. 
Pri preprečevanju z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh je bilo zdravljenje najpogosteje povezano z astenijo, ki ji je sledilo zvišanje telesne temperature in glavobol.
The median time to relapse was 26 days with a dose of 6 mg. 
Mediana časa do relapsa pri odmerku 6 mg je bila 26 dni.
• if you have high or low levels of vitamin D, calcium or any other minerals 
• če imate visoke ali nizke koncentracije vitamina D, kalcija ali drugih mineralov;
No difference was observed in the indicators of renal function. 
Pri kazalcih ledvične funkcije razlik niso opazili.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch 
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca,
Consideration should be given to the severity of the hypercalcaemia as well as the tumour type. 
Presoditi je treba o stopnji hiperkalciemije in tudi o tipu tumorja.
Take your tablet at least 6 hours after you had last had anything to eat, drink or any other medicines or supplements except water. 
Vzemite vašo tableto vsaj 6 ur po vašem zadnjem zaužitem obroku, pijači, kateremkoli zdravilu ali dodatku razen vodi.
Do not take Iasibon with food or any other drinks except plain water as Iasibon is less effective if it is taken with food or drink (see section 3). 
Ne jemljite zdravila Iasibon s hrano ali katero koli drugo pijačo razen vodo, ker lahko jemanje zdravila s hrano ali pijačo povzroči, da je zdravilo Iasibon manj učinkovito (glejte poglavje 3).
Clinical studies have not shown any evidence of deterioration in renal function with long term Iasibon therapy. 
Klinične študije niso pokazale, da bi pri dolgotrajnem zdravljenju z zdravilom Iasibon prišlo do poslabšanja ledvične funkcije.
The dose should be infused over at least 15 minutes. 
Odmerek infundiramo vsaj 15 minut.
The liver has no significant role in the clearance of ibandronic acid since it is not metabolized but is cleared by renal excretion and by uptake into bone. 
Jetra niso pomembna za očistek ibandronske kisline, ker se ne presnavlja, ampak izloča z renalno ekskrecijo in vstopanjem v kostno tkivo.
• memory loss 
• izguba spomina,
All Skeletal Related Events (SREs) Placebo n=277 
Vsi z okostjem povezani dogodki (SREs) Placebo n = 277
A shorter (i.e. 15 min) infusion time should only be used for patients with normal renal function or mild renal impairment. 
15 min) se uporablja samo pri bolnikih z normalno ledvično funkcijo ali blago ledvično okvaro.
In clinical pharmacology trial WP18551, after a single dose intravenous administration of 6 mg (15 minutes infusion), mean AUC0-24 increased by 14% and 86%, respectively, in subjects with mild (mean estimated CLcr=68.1 mL/min) and moderate (mean estimated CLcr=41.2 mL/min) renal impairment compared to healthy volunteers (mean estimated CLcr=120 mL/min). 
V kliničnem farmakološkem preskušanju WP18551 se je po enkratnem 6-mg odmerku, danem intravensko (15 minutna infuzija), povprečna vrednost AUC0-24 pri ljudeh z blago ledvično okvaro (ocenjeno povprečje CLcr = 68,1 ml/min) povečala za 14 %, pri ljudeh z zmerno ledvično okvaro (ocenjeno povprečje CLcr = 41,2 ml/min) pa za 86 % v primerjavi z zdravimi prostovoljci (ocenjeno povprečje CLcr = 120 ml/min).
Clinical studies in the treatment of tumour-induced hypercalcaemia Clinical studies in hypercalcaemia of malignancy demonstrated that the inhibitory effect of ibandronic acid on tumour-induced osteolysis, and specifically on tumour-induced hypercalcaemia, is characterised by a decrease in serum calcium and urinary calcium excretion. 
Klinične študije zdravljenja tumorsko povzročene hiperkalciemije Klinične študije hiperkalciemije zaradi malignosti so pokazale, da je za zaviralni učinek ibandronske kisline na tumorsko povzročeno osteolizo in še posebno na hiperkalciemijo, povzročeno s tumorjem, značilno znižanje serumskega kalcija in zmanjšano izločanje kalcija z urinom.
Iasibon tablets contain lactose and should not be administered to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. 
Tablete Iasibon vsebujejo laktozo, zato jih ne smemo dajati bolnikom z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze in galaktoze.
* Note albumin-corrected serum calcium concentrations are calculated as follows: 
*Opomba: koncentracije korigiranega kalcija v serumu izračunamo po naslednjih formulah:
At doses that were considerably higher than the pharmacologically effective doses, ibandronic acid did not have any effect on bone mineralisation. 
Pri odmerkih, ki so bili precej višji od farmakološko učinkovitih odmerkov, ibandronska kislina ni vplivala na mineralizacijo kosti.
After a 2 hour infusion of 2, 4 and 6 mg ibandronic acid pharmacokinetic parameters are dose proportional. 
Pri dvournih infuzijah 2, 4 in 6 mg ibandronske kisline so bili farmakokinetični parametri odvisni od velikosti odmerka.
What Iasibon is and what it is used for. 
Kaj je zdravilo Iasibon in za kaj ga uporabljamo
• a condition affecting the blood vessels in your brain called ‘cerebrovascular disorder' (stroke or brain bleeding) 
• stanje, ki prizadene žile v možganih, imenovano »cerebrovaskularna bolezen« (kap ali krvavitev iz možganov),
Ibandronic acid dose 
odmerek ibandronske kisline
Possible side effects Like all medicines, this medicine can cause side effects although not everybody gets them. 
Možni neželeni učinki Kot vsa zdravila ima lahko tudi to zdravilo Iasibon neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
After initial systemic exposure, ibandronic acid rapidly binds to bone or is excreted into urine. 
Po prvotni sistemski izpostavljenosti se ibandronska kislina hitro veže v kostno tkivo ali pa se izloči skozi ledvice.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo IasibonObvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
The primary endpoint of the trial was the skeletal morbidity period rate (SMPR). 
Primarni cilj raziskave je bil stopnja hitrosti obolevnosti okostja (SMPR - skeletal morbidity period rate).
This could be a sign of an ulcer of the first section of the bowel (duodenum) 
Te so lahko znak, da razjeda v začetnem delu črevesa (dvanajstniku)
Appropriate medical support and monitoring measures should be readily available when Iasibon intravenous injection is administered. 
Pri dajanju intravenske injekcije zdravila Iasibon mora biti na voljo ustrezna medicinska podpora in nadzor.
If you have moderate kidney problems, your doctor may reduce your dose to one tablet every other day. 
Če imate blage težave z ledvicami, vam bo morda vaš zdravnik zmanjšal odmerek na eno tableto vsak drugi dan.
Only clear solution without particles should be used. 
Uporabi se lahko samo bistra raztopina, brez delcev.
Biotransformation There is no evidence that ibandronic acid is metabolized in animals or humans. 
Biotransformacija Ni dokazov, da bi se ibandronska kislina pri ljudeh in živalih presnavljala.
• hair loss 
• izguba las,
Less frequently, decrease in serum calcium below normal range (hypocalcaemia) is reported. 
Manj pogosto poročajoo znižanju serumskega kalcija pod spodnjo mejo normale (hipokalciemija).
The unabsorbed fraction of ibandronic acid is eliminated unchanged in the faeces. 
Neabsorbirani delež ibandronske kisline se izloči nespremenjen s fecesom.
There was also a 38% reduction in the risk of developing an SRE for Ibandronate treated patients when compared with placebo (relative risk 0.62, p=0.003). 
V primerjavi s placebom je bilo tveganje za nastanek SRE pri bolnikih, zdravljenih z ibandronsko kislino, za 38 % manjše (relativno tveganje 0,62, p = 0,003).
Further, as protein binding of ibandronic acid is approximately 87% at therapeutic concentrations, hypoproteinaemia in severe liver disease is unlikely to lead to clinically significant increases in free plasma concentration. 
Vezava ibandronske kisline na beljakovine pri terapevtskih koncentracijah je približno 87-%, zato hipoproteinemija pri bolnikih s hudo jetrno okvaro verjetno ne povzroča klinično značilnih povišanj prostih plazemskih koncentracij.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless reconstitution has taken place in controlled and validated aseptic conditions. 
V normalnih razmerah naj zdravila ne bi shranjevali dlje kot 24 ur pri 2 do 8 °C, razen če je bila priprava opravljena v nadzorovanih in validiranih aseptičnih pogojih.
≥50 CLcr <80 6 mg (6 ml of concentrate for solution for infusion) 
≥50 CLcr < 80 6 mg (6 ml koncentrata za raztopino za infundiranje)
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. 
Pri bolnikih, pri katerih se med zdravljenjem z difosfonati pojavi osteonekroza čeljustnic, lahko zobne operacije stanje poslabšajo.
Clinically relevant hypocalcaemia should be corrected by intravenous administration of calcium gluconate. 
Klinično pomembno hipokalciemijo je treba popraviti z intravenskim dajanjem kalcijevega glukonata.
Ibandronate 50 mg n=287 
Ibandronska kislina 50 mg n = 287
• headache, feeling dizzy or feeling weak 
• glavobol, vrtoglavica ali občutek šibkosti,
This is because the medicine will only work if it is taken all the time. 
Zdravilo Iasibon jemljite tako dolgo, kot vam je naročil zdravnik, kajti zdravilo bo delovalo le, če ga boste jemali ves čas.
• sleep problems, feeling anxious, emotional instability, or mood swings 
• težave s spanjem, občutek zaskrbljenosti, čustvena nestabilnost ali menjava razpoloženja, • kožni izpuščaj,
• a type of antibiotic injection called “aminoglycoside” such as gentamicin. 
• antibiotik v obliki injekcije iz skupine aminoglikozidov, kot je gentamicin.
This leaflet was last revised in {MM/YYYY} 
Navodilo je bilo nazadnje revidiranoodobreno
Patients with hepatic impairment (see section 4.2) 
Bolniki z jetrno okvaro (glejte poglavje 4.2)
Therefore, Iasibon should not be used during pregnancy. 
Zato se zdravila Iasibon med nosečnostjo ne sme uporabljati.
Female patients with breast cancer and radiologically confirmed bone metastases were randomised to receive placebo (158 patients) or 6 mg Ibandronate (154 patients). 
Bolnice z rakom dojke in radiološko potrjenimi metastazami v kosteh so prejemale placebo (158 bolnic) ali 6 mg ibandronske kisline (154 bolnic).
Exposure to ibandronic acid in patients with various degrees of renal impairment is related to creatinine clearance (CLcr). 
Izpostavljenost ibandronski kislini pri bolnikih z različnimi stopnjami ledvične okvare je povezana s kreatininskim očistkom (CLcr).
There are no data available characterising the use of a shorter infusion time in patients with creatinine clearance below 50 ml/min. 
Podatkov, ki bi označevali uporabo krajšega časa infuzije pri bolnikih z očistkom kreatinina pod 50 ml/min, ni na voljo.
• tooth problems. 
• kožne težave, • težave z zobmi.
• heart and circulatory problems (including palpitations, heart attack, hypertension (high blood pressure) and varicose veins) 
• težave s srcem in obtočili (vključno s palpitacijami, srčno kapjo, hipertenzijo (zvišanim krvnim tlakom) in krčnimi žilami),
≥30 CLcr <50 4 mg (4 ml of concentrate for solution for infusion) 
≥30 CLcr < 50 4 mg (4 ml koncentrata za raztopino za infundiranje)
However, early plasma levels fall quickly, reaching 10% of peak values within 3 and 8 hours after intravenous or oral administration respectively. 
Zgodnje plazemske koncentracije hitro padejo, 10 % največje vrednosti dosežejo 3 ure po intravenskem in 8 ur po peroralnem dajanju.
For patients with severe renal impairment (CLcr <30 mL/min) the recommended dose is one 50 mg film-coated tablet once weekly. 
Pri bolnikih s hudo ledvično okvaro (CLcr < 30 ml/min) je priporočeni odmerek ena 50 mg filmsko obložena tableta enkrat na teden.
What Iasibon looks like and contents of the pack Iasibon is a colourless, clear solution. 
Izgled zdravila Iasibon in vsebina pakiranja Zdravilo Iasibon je brezbarvna, bistra raztopina.
Female patients with breast cancer and radiologically confirmed bone metastases were randomised to receive placebo (277 patients) or 50 mg Ibandronate (287 patients). 
Bolnice z rakom dojke in radiološko potrjenimi metastazami v kosteh so prejemale placebo (277 bolnic) ali 50 mg ibandronske kisline (278 bolnic).
• It is given as an infusion into your vein 
• Aplicira se v obliki infuzije v veno.
Subjects with severe renal impairment (CLcr ≤ 30 mL/min) receiving oral administration of 10 mg ibandronic acid daily for 21 days, had 2-3 fold higher plasma concentrations than subjects with normal renal function (CLcr ≥80 mL/min). 
Bolniki s hudo motnjo ledvičnega delovanja (CLcr ≤ 30 ml/min), ki so peroralno prejemali 10 mg ibandronske kisline na dan 21 dni, so imeli 2 do 3-krat višje plazemske koncentracije kot osebe z normalno ledvično funkcijo (CLcr ≥ 80 ml/min).
Iasibon is indicated in adults for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. 
Zdravilo Iasibon je indiciran pri odraslih za preprečevanje z okostjem povezanih dogodkov (patološke frakture, zapleti, pri katerih je potrebno obsevanje ali kirurški poseg) pri bolnikih z rakom dojke in metastazami v kosteh.
• high levels of urea or high levels of parathyroid hormone in your blood. 
• visoke koncentracije sečnine ali visoke koncentracije obščitniškega hormona v krvi.
- Patients should not lie down for 60 minutes after taking Iasibon. 
- Po zaužitju zdravila Iasibon bolniki 60 minut ne smejo leči.
Dose: Treatment of tumour-induced hypercalcaemia Iasibon is usually administered in a hospital setting. 
Odmerjanje: zdravljenje tumorsko povzročene hiperkalciemije Dajanje zdravila Iasibon običajno poteka v bolnišnici.
What Iasibon looks like and contents of the pack The film-coated tablets are white, round biconvex tablets supplied in Polyamide/Al/PVC - Aluminum foil blister. 
Filmsko obložene tablete so bele, okrogle, bikonveksne tablete na voljo v poliamid/Al/PVCaluminijasto folijo.
• Stay upright (sitting or standing) position while taking your tablet and for the next hour (60 minutes). 
• med jemanjem tablete in še naslednjo uro (60 minut) ostanete v pokončnem položaju (stoje ali sede).
Urinary concentrations of the bone resorption marker CTx (C-terminal telopeptide released from Type I collagen) were significantly reduced in the Ibandronate group compared to placebo. 
Koncentracije označevalca resorpcije kosti CTx (C-terminalni telopeptid, ki se sprosti s kolagena tipa I) v seču so bile v skupini zdravljeni z ibandronsko kislino v primerjavi s placebom značilno znižane.
Ibandronate 6 mg n=154 
Ibandronska kislina 6 mg n = 154
• itching or tingling skin (paraesthesia) 
• srbenje ali ščemenje kože (parestezija),
Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Iasibon is given to patients with active upper gastrointestinal problems (e.g. known Barrett's oesophagus, dysphagia, other oesophageal diseases, gastritis, duodenitis or ulcers). 
Zaradi možnega draženja in poslabšanja osnovne bolezni je pri dajanju zdravila Iasibon bolnikom z aktivnimi težavami v zgornjem delu prebavne cevi (npr. Barrettov požiralnik, disfagija, druge bolezni ezofagusa, gastritis, duodenitis ali razjede) potrebna previdnost.
The medicine should be administered as an infusion in your vein over two hours. 
Zdravilo se daje v obliki infuzije v veno, ki traja dve uri.
You may have early signs of a possible unusual fracture of the thigh bone. 
To so lahko zgodnji znaki možnega netipičnega zloma stegnenice.
Only clear solutions without particles should be used. 
Uporabljamo lahko le bistre raztopine brez delcev.
Do not chew, suck or crush the tablet. 
Tablet ne žvečite, sesajte ali drobite.
Your doctor will work out how much Iasibon you will be given depending on your illness. 
Koliko zdravila vzeti Glede na vašo bolezen bo vaš zdravnik presodil, koliko zdravila Iasibon boste prejeli.
• dry mouth, strange taste in your mouth or difficulty swallowing 
• suha usta, čuden okus v ustih ali težave pri požiranju, • anemija,
In the dose range recommended for treatment, the following response rates with the respective confidence intervals have been shown in clinical trials for patients with baseline albumin-corrected serum calcium ≥ 3.0 mmol/l after adequate rehydration. 
V razponih odmerkov, priporočenih za zdravljenje, so med kliničnimi preskušanji za bolnike, ki so pred začetkom zdravljenja imeli korigirani kalcij v serumu ≥ 3,0 mmol/l po ustrezni rehidraciji,
Clinically relevant hypocalcaemia (very low serum calcium levels) should be corrected by intravenous administration of calcium gluconate. 
Klinično pomembno hipokalciemijo (zelo nizke koncentracije kalcija v serumu) je treba popraviti z intravenskim dajanjem kalcijevega glukonata.
It is not known whether ibandronic acid is excreted in human milk. 
Ni znano, ali se ibandronska kislina izloča v materino mleko.
Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those expected for this class of medicinal products (bisphosphonates). 
Neželeni učinki ibandronske kisline v študijah vplivov na sposobnost za razmnoževanje pri podganah so bili pričakovano značilni za to vrsto zdravil (difosfonati).
= Serum calcium (mg/dl) + 0.8 x [4 - albumin (g/dl)] 
= koncentracija kalcija v serumu (mg/dl) + 0,8 x [4albumin (g/dl)]
• flu-like symptoms, including fever, shaking and shivering, feeling of discomfort, fatigue, bone pain and aching muscles and joints. 
• gripi podobni simptomi, vključno z zvišano telesno temperaturo, mrzlico in drgetanjem, občutjem nelagodja, utrujenostjo, bolečino v kosteh, mišicah in sklepih.
In healthy male volunteers and postmenopausal women, intravenous ranitidine caused an increase in ibandronic acid bioavailability of about 20% (which is within the normal variability of the bioavailability of ibandronic acid), probably as a result of reduced gastric acidity. 
Antagonisti histaminskih receptorjev H2 in zaviralci protonske črpalke Pri zdravih moških prostovoljcih in ženskah v postmenopavzi je intravenski ranitidin povečal biološko uporabnost ibandronske kisline za 20 % (kar je znotraj normalne variabilnosti biološke uporabnosti ibandronske kisline).
No specific information is available on the treatment of overdosage with Iasibon. 
Za ravnanje pri prevelikem odmerjanju z zdravilom Iasibon ni posebnih priporočil.
This is because Iasibon can affect the way some other medicines work. 
Zdravilo Iasibon lahko vpliva na delovanje drugih zdravil.
No dose adjustment is necessary (see section 5.2). 
Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
Milk or antacids should be given to bind Iasibon. 
Za vezavo zdravila Iasibon je treba zaužiti mleko ali antacide.
• a heart rhythm problem called ‘bundle branch block' 
• težava s srčnim ritmom, imenovana »kračni blok«,
Iasibon therapy should only be initiated by physicians experienced in the treatment of cancer. 
Zdravljenje z zdravilom Iasibon lahko začne le zdravnik, ki ima izkušnje z zdravljenjem raka.
Tests for genotoxicity revealed no evidence of genetic activity for ibandronic acid. 
Študije genotoksičnosti niso pokazale genetske aktivnosti ibandronske kisline.
• your body temperature getting too low (‘hypothermia') 
• prenizka telesna temperatura (hipotermija),
What you need to know before you take Iasibon. 
Kaj morate vedeti, preden boste vzeli zdravilo Iasibon
Protein binding in human plasma is approximately 87% at therapeutic concentrations, and thus interaction with other medicinal products, due to displacement is unlikely. 
Vezava na plazemske beljakovine pri ljudeh je pri terapevtskih koncentracijah približno 87-%, zato so medsebojna delovanja z drugimi zdravili zaradi izpodrivanja malo verjetna.
2 mg (2 ml of concentrate for solution for infusion) 
2 mg (2 ml koncentrata za raztopino za infundiranje)
A flu-like syndrome consisting of fever, chills, bone and/or muscle ache-like pain has occurred. 
Pojavil se je gripi podobni sindrom, ki je vključeval vročino, mrzlico, bolečino v mišicah in/ali kosteh.
All Skeletal Related Events (SREs) Placebo n=158 
Vsi z okostjem povezani dogodki (SREs) Placebo n = 158
The overall adverse event profile of ibandronic acid following the 15 minute infusion was consistent with the known safety profile over longer infusion times and no new safety concerns were identified relating to the use of a 15 minute infusion time. 
Celoten profil neželenih dogodkov po 15 minutni infuziji je bil skladen z znanim varnostnim profilom pri daljši infuziji.
• pain or sore in your mouth or jaw. 
• bolečina ali razjeda v vaših ustih ali čeljusti.
- Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases 
• preprečevanje z okostjem povezanih dogodkov (patološke frakture; zapleti, pri katerih je potrebno obsevanje ali kirurški poseg) pri bolnikih z rakom dojke in metastazami v kosteh,
You may have early signs of severe jaw problems (necrosis 
Lahko imate zgodnje znake hudih težav s čeljustjo
Posology The recommended dose is one 50 mg film-coated tablet daily. 
Priporočeni odmerek je ena 50 mg filmsko obložena tableta na dan.
A tabular summary of the secondary efficacy results is presented in Table 3. 
Preglednica 3 nudi tabelaričen pregled sekundarnih rezultatov učinkovitosti.
No systemic accumulation was observed when ibandronic acid was administered intravenously once every 4 weeks for 48 weeks to patients with metastatic bone disease. 
Po intravenskem dajanju ibandronske kisline enkrat na 4 tedne 48 tednov bolnikom z metastatično boleznijo kosti sistemske kumulacije niso opazili.
- Water is the only drink that should be taken with Iasibon. 
- Vodaje edina tekočina, ki jo lahko bolnik zaužije z zdravilom Iasibon.
Patients with known hypersensitivity to other bisphosphonates Caution is to be taken in patients with known hypersensitivity to other bisphosphonates. 
Bolniki z znano preobčutljivostjo za druge difosfonate Previdnost je potrebna pri bolnikih z znano preobčutljivostjo za druge difosfonate.
In reproductive studies in rats by the oral route, effects on fertility consisted of increased preimplantation losses at dose levels of 1 mg/kg/day and higher. 
V študijah vplivov na sposobnost razmnoževanja pri podganah s peroralnim dajanjem je vpliv na plodnost predstavljala povečana izguba pred vgnezditvijo pri odmerkih 1 mg/kg/dan ali večjih.
This medicinal product does not require any special storage conditions prior to reconstitution. 
Zdravilo pred rekonstitucijo ne potrebuje posebnih pogojev shranjevanja.
Frequency of administration 
Pogostnost dajanja
Iasibon should not be used during breast-feeding. 
Zdravila Iasibon se ne sme uporabljati med dojenjem.
Iasibon is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases'). 
Zdravilo Iasibon uporabljamo pri odraslih in vam ga bodo predpisali, če imate raka dojke, ki se je razširil na kosti (metastaze v kosteh).
• tablet core: povidone, microcrystalline cellulose, crospovidone, maize starch pregelatinised, 
• Jedro tablet: povidon, mikrokristalna celuloza, krospovidon, koruzni škrob (predgelirani), gliceroldibehenat, brezvodni koloidni silicijev dioksid.